ライフサイエンスコーパス: yohimbine

1 to estimate the kinetic parameters of (11)C-yohimbine.

2 leotide are unaffected in cells treated with yohimbine.

3 h anxiety disorders who were challenged with yohimbine.

4 effect of F was blocked by both naloxone and yohimbine.

5 healthy subjects following administration of yohimbine.

6 the alpha 2 adrenergic selective antagonist yohimbine.

7 cipitated by the alpha 2-receptor antagonist yohimbine.

8 , and to compare these effects with those of yohimbine.

9 ing were not modulated by hydrocortisone and yohimbine.

10 .4 +/- 5 muM with addition of the antagonist yohimbine.

11 tion of the alpha(2)-adrenoceptor antagonist yohimbine.

12 by pharmacological challenge with unlabeled yohimbine (0.3 mg/kg).

13 bjects (n = 10), following administration of yohimbine (0.4 mg/kg) or placebo in a randomized, double

14 r injections of the pharmacological stressor yohimbine (0.5-2 mg/kg) or pellet priming (1-4 noncontin

15 Selective alpha2-adrenoceptor blockade with yohimbine (0.6-1.0 mg/kg i.v.) or rauwolscine (1.0 mg/kg

16 alpha 2-antagonists, idazoxan (1 microM) and yohimbine (1 microM).

17 demonstrated that systemic administration of yohimbine (1.0 mg/kg) facilitated a long-term decrease i

18 the alpha(2)-adrenergic receptor antagonist, yohimbine (1.0 microm), and attenuated by the alpha(2)-a

19 alpha(2)-adrenergic autoreceptor antagonist, yohimbine (1.0 microM), caused an increase in the oxidat

20 ) 5 mM BH(4) + adrenoreceptor blockade (5 mM yohimbine + 1 mM propranolol).

21 ment with the alpha2 adrenoceptor antagonist yohimbine (10 micro M), and occluded partially by the al

22 e occurs within 12 h of exposure of cells to yohimbine (100 microM), and by 48 h tyrosinase activity

23 were reversed by phentolamine (3 microM) or yohimbine (100 nM), but not propranolol (10 microM), whe

24 ciated with pellet delivery (pellet cue), or yohimbine (2 mg/kg, a pharmacological stressor).

25 hock stress and the pharmacological stressor yohimbine (2 mg/kg, i.p.) induce reinstatement of nicoti

26 osing animals to a pharmacological stressor, yohimbine (2.5 mg/kg, i.p.), alone and in combination wi

27 Pretreatment with yohimbine (2mg/kg, i.p.) enhanced the shaking induced by

28 The alpha(2) receptor antagonist, yohimbine (3 microg/microl, icv) also prevented the decr

29 Yohimbine (3 microgram/5 microliter, icv, n=8) pretreatm

30 However, i.c.v. pretreatment with yohimbine (30 microg) had no effect on improgan antinoci

31 iloride analogues on the dissociation of [3H]yohimbine, [3H]rauwolscine, and [3H]RX821002.

32 blocked by the alpha-2 adrenergic antagonist yohimbine, 5 mg/kg, i.p.; that of F by the opioid antago

33 1.7 nM), MK-912 (4.8 nM), BRL-44408 (15 nM), yohimbine (63 nM), ARC-239 (540 nM), prazosin (4900 nM),

34 ment with the alpha 2-adrenergic antagonist, yohimbine (8 micrograms, I.C.V.), blocked the attenuatin

35 selective alpha1-adrenergic antagonist, and yohimbine, a selective alpha2-adrenergic antagonist, als

36 dy from this laboratory suggested that (11)C-yohimbine, a selective alpha2-adrenoceptor antagonist, i

37 Yohimbine, a specific alpha2-adrenergic antagonist, comp

38 The alpha2-adrenoreceptor antagonist yohimbine abolished CSH-induced enhancement of NE inhibi

39 ggesting that an intact cell is required for yohimbine action.

40 These findings suggest that yohimbine acts through an as yet unidentified signaling

41 treatment with a combination of BIBP3226 and yohimbine almost completely antagonized the NPY-mediated

42 -arginine or the combination of prazosin and yohimbine alone did not affect the diameter of tracheal

43 nd thus habitual), whereas hydrocortisone or yohimbine alone have no such effect.

44 ist) antinociception was blocked not only by yohimbine (alpha 2-antagonist) but also by PACPX (A1-ant

45 X (A1-antagonist), respectively, but also by yohimbine (alpha 2-antagonist).

46 stration of terazosin (alpha(1)-antagonist), yohimbine (alpha(2)-antagonist), phentolamine (non-selec

47 be reversed by intrathecal administration of yohimbine (alpha-2-adrenoceptor antagonist).

48 a receptor blockers prazosin (alpha1) and/or yohimbine (alpha2).

49 Yohimbine also enhanced the inhibitory effect of F.

50 s tested in these two brain areas; prazosin, yohimbine, amphetamine, SKF 38393 and SCH 23390 had no e

51 Yohimbine (an alpha 2 antagonist) microperfusion into th

52 zosin (an alpha(1)-adrenoceptor antagonist), yohimbine (an alpha(2)-adrenoceptor antagonist) and phen

53 r injections of the pharmacological stressor yohimbine (an alpha-2 andrenoceptor antagonist) or pelle

54 Preinjection of yohimbine, an alpha 2-adrenergic antagonist, completely

55 zosin, an alpha 1-adrenergic antagonist, nor yohimbine, an alpha 2-specific antagonist, was as effect

56 Yohimbine, an alpha(2)-adrenoeceptor antagonist, did not

57 aggregation, which was further inhibited by yohimbine, an alpha(2A)-adrenergic receptor antagonist.

58 nts with rat subjects examined the effect of yohimbine, an alpha-2 adrenergic autoreceptor antagonist

59 an alpha1-antagonist, but was unaffected by yohimbine, an alpha2-antagonist.

60 As anticipated, yohimbine, an inhibitor of alpha(2)ARs, blocked this pot

61 Methiothepin, yohimbine and cyanopindolol also blocked 5-CT-stimulated

62 The alpha2-AR antagonists yohimbine and idazoxan reduced clonidine's effect on V1/

63 ist WB4101, alpha(2) adrenoceptor antagonist yohimbine and mu-opioid receptor antagonist naltrexone f

64 gnificant difference in memory score between yohimbine and placebo groups.

65 s were blocked by previous administration of yohimbine and propranolol.

66 ng of the most efficacious inverse agonists, yohimbine and rauwolscine, was 1.7- and 2.1-fold weaker.

67 All effects of NA were blocked by yohimbine and synaptic transmission was reduced by cloni

68 In MSA patients, the pressor response to yohimbine and the decrease in SBP with 1 mg/min trimetha

69 group as a whole (subjects who had received yohimbine and those who had received placebo) and for th

70 eptor agonist, UK 14,304 (1.0 microm), while yohimbine and UK 14,304 had little effect in MV; (v) coc

71 amethonium (300 microM), but were reduced by yohimbine and usually blocked by the further addition of

72 ranolol), alpha-adrenergic (phentolamine and yohimbine), and nitric oxide (NG-monomethyl-L-arginine,

73 HCl, 50 mM caffeine, and 1 mM each nicotine, yohimbine, and strychnine, plus a number of non-alkaloid

74 Yohimbine- and pellet-priming-induced reinstatement was

75 Yohimbine antagonized the clonidine-mediated adenylyl cy

76 The results provide moderate support for yohimbine as a therapeutic augmentation strategy for exp

77 Yohimbine augmentation, relative to placebo augmentation

78 was pretreated with alpha2-receptor blocker, yohimbine, before injection of alphaMNE.

79 positron emission tomography (PET) of [(11)C]yohimbine binding in brain to quantify the density and a

80 The maps of (11)C-yohimbine binding to alpha2 adrenoceptors in human brain

81 However, two sequential doses of yohimbine blocked LH-induced antinociception on both tes

82 Treatment of melanocyte cultures with yohimbine blocks the increase in tyrosinase activity by

83 ments performed using the alpha 2-antagonist yohimbine confirmed that the effects of UK were mediated

84 ximately 60%, and the effect was reversed by yohimbine, confirming that it was mediated by activation

85 s reproduced by clonidine and antagonized by yohimbine, consistent with contribution of alpha2 adrene

86 potency: cyanopindolol >/= methiothepin >>> yohimbine, consistent with rat 5-HT(1B) receptor pharmac

87 It was found that peripheral or intra-BSTv yohimbine did increase anxiety-related behavior in postp

88 Preapplication of naloxone and yohimbine did not block the interaction.

89 wever, Experiments 3 and 4 demonstrated that yohimbine did not eradicate the original fear learning:

90 30%, whereas alpha(2)-adrenergic antagonist, yohimbine, did not prevent the stimulatory effects of NE

91 ect of competition between two amilorides on yohimbine dissociation also was explored.

92 The estimated maximal increase in the [3H]yohimbine dissociation rate caused by the 5-N-alkyl amil

93 ation of a melanosome-enriched fraction with yohimbine does not cause a lowering of tyrosinase activi

94 Tyrosinase inhibition by yohimbine does not involve a decrease in substrate avail

95 results of western immunoblotting show that yohimbine does not significantly lower the amount of tyr

96 Yohimbine dose-dependently decreased advantageous respon

97 L-allylglycine, sodium lactate infusions or yohimbine elicits panic-like responses (i.e., anxiety, t

98 n with anxiety disorders, as demonstrated by yohimbine-exacerbated anxiety.

99 s confirm the usefulness of the tracer (11)C-yohimbine for mapping alpha2 adrenoceptors in human brai

100 n order of inverse efficacy of rauwolscine > yohimbine > RX821002 > MK912, whereas phentolamine and i

101 In glabrous skin, yohimbine had no effect on an equivalent thermal inflamm

102 [(35)S]GTPgammaS binding by themselves while yohimbine had weak partial agonist activity.

103 lity since tyrosine uptake studies show that yohimbine has no effect on the amount of tyrosine enteri

104 Yohimbine has not yet been investigated in the augmentat

105 xiety disorder were randomized to placebo or yohimbine HCl (10.8 mg) 1 hour before each of four expos

106 cts each received an intravenous infusion of yohimbine hydrochloride (0.4 mg/kg), m-CPP (1.0 mg/kg),

107 Yohimbine hydrochloride produces marked behavioral and c

108 Presence of a blunted GH response to yohimbine in children with anxiety disorders is reminisc

109 ptor availability by means of PET with (11)C-yohimbine in healthy male adults.

110 nt difference in brain metabolic response to yohimbine in patients with PTSD compared with healthy su

111 ced norepinephrine release in the brain with yohimbine in patients with PTSD.

112 mpled arterial blood to measure intact (11)C-yohimbine in plasma.

113 ease as the alpha(2)-adrenoceptor antagonist yohimbine increased the probability of occurrence of NCT

114 ered either the alpha2-adrenergic antagonist yohimbine (increasing noradrenergic stimulation), hydroc

115 ion in activity when incubated directly with yohimbine, indicating that the drug does not act as a di

116 Moreover, yohimbine-induced cocaine-seeking behavior is BNST-depen

117 The yohimbine-induced decrease in tyrosinase activity is rev

118 Our results demonstrate yohimbine-induced depression of excitatory transmission

119 Recent studies show yohimbine-induced drug-seeking behavior is attenuated by

120 Yohimbine-induced enhancement of sympathetic tone in pat

121 Dorsal mPFC light delivery attenuated yohimbine-induced Fos immunoreactivity and disrupted neu

122 e ex vivo effects are paralleled in vivo, as yohimbine-induced impairment of cocaine-CPP extinction i

123 s, the CORT-treated rats tended to have more yohimbine-induced impulsive responses at low doses on th

124 Yohimbine-induced impulsivity on the 5CSRTT and biochemi

125 of mifepristone on maintained responding and yohimbine-induced increases in responding for ethanol an

126 In contrast, baseline consumption, yohimbine-induced increases in responding, and circulati

127 rBNI injected locally into the BLA prevented yohimbine-induced nicotine CPP reinstatement without aff

128 ortex and the caudate nucleus with high-dose yohimbine-induced norepinephrine release, but low levels

129 (42%) of the patients with PTSD experienced yohimbine-induced panic attacks and had significantly gr

130 Yohimbine-induced panic attacks tended to occur in diffe

131 e groups of rats and animals were tested for yohimbine-induced reinstatement and corticosterone relea

132 the effect of the NK1R antagonist L822429 on yohimbine-induced reinstatement of alcohol or cocaine se

133 istar rats, we found that L822429 attenuates yohimbine-induced reinstatement of alcohol seeking, but

134 We observed a similar suppression of yohimbine-induced reinstatement of cocaine seeking by L8

135 e also observed a significant attenuation of yohimbine-induced reinstatement of cocaine-seeking after

136 infusions into the central amygdala (CeA) on yohimbine-induced reinstatement of ethanol- and sucrose-

137 BLA) mifepristone administration suppressed yohimbine-induced reinstatement of ethanol-seeking, whil

138 rtant role in the effects of mifepristone on yohimbine-induced reinstatement of ethanol-seeking.

139 Dorsal mPFC light delivery attenuated yohimbine-induced reinstatement of food seeking in eNpHR

140 ctivated GFP-negative mPFC neurons following yohimbine-induced reinstatement of food seeking.

141 ucrose, and attenuated cue-, footshock-, and yohimbine-induced reinstatement.

142 nduced reinstatement of food seeking but not yohimbine-induced reinstatement.

143 Higher dosage of yohimbine inhibited the baseline expression of bFGF.

144 ggests that alpha 2-adrenoceptors blocked by yohimbine injected I.C.V. do not appear to have a tonic

145 Assignment of the IRE-yohimbine interaction as the origin of this effect was s

146 Because yohimbine is a weak 5HT1A receptor agonist, other groups

147 adrenergic receptor (alpha(2)-AR) antagonist yohimbine is a widely used tool for the study of anxioge

148 lo[2,3-alpha]quinolizidine skeleton found in yohimbine is described.

149 Preclinical and clinical trials suggest that yohimbine may augment extinction learning without signif

150 and demonstrate that some of the actions of yohimbine may be directly dependent upon orexin signalin

151 y produced by morphine was reduced by either yohimbine, methysergide or atropine.

152 neither the alpha(2)-adrenoceptor antagonist yohimbine nor the alpha(1)-adrenoceptor antagonist WB410

153 The calculated log affinities at the yohimbine-occupied receptor ranged from 1.75 for 5-(N-et

154 The increase in affinity found at the yohimbine-occupied receptor was not correlated with incr

155 itro, the effects of the alpha(2) antagonist yohimbine on improgan antinociception were presently stu

156 failure (PAF), we studied the effect of oral yohimbine on seated systolic blood pressure (SBP), the e

157 avenous infusions of the noradrenergic agent yohimbine or by direct injections of NMDA into the DMH.

158 red maternal behavior after BSTv infusion of yohimbine or idazoxan cannot both be readily explained b

159 d in postpartum rats after administration of yohimbine or idazoxan.

160 derlie the disrupted mothering of dams given yohimbine or idazoxan.

161 slides, subjects received either intravenous yohimbine or intravenous placebo in a double-blind rando

162 d when the alpha(2)-adrenoceptor antagonists yohimbine or rauwolscine were co-administered, suggestin

163 ortisone, the alpha2-adrenoceptor antagonist yohimbine, or both before they were trained in two instr

164 with propranolol, but neither phentolamine, yohimbine, or L-NMMA altered this response.

165 Tv) with the alpha2-autoreceptor antagonist, yohimbine, or the more selective alpha2-autoreceptor ant

166 and 15 normal comparison children were given yohimbine orally (0.1 mg/kg).

167 We find that, as with yohimbine, orexin A depression of excitatory transmissio

168 Here, we investigated yohimbine-orexin interactions.

169 rcise (end fear), such that the advantage of yohimbine over placebo was only evident among patients w

170 We previously demonstrated that yohimbine paradoxically depresses excitatory transmissio

171 tricyclic antidepressants are combined with yohimbine (Pausinystalia yohimbe); potentiation of oral

172 sure to forskolin, isoproterenol, clonidine, yohimbine, pertussis toxin, and the NO donor spermine-NO

173 After yohimbine plus cue reinstatement, the actions of CRF-R2

174 In contrast, intrathecal (i.t.) yohimbine pretreatment (30 microg) completely blocked th

175 Systemic yohimbine pretreatment (4 mg/kg, i.p.) completely blocke

176 other group of seven subjects, administering yohimbine prior to phentolamine resulted in similar find

177 Solutions of yohimbine + propranolol (Y + P), bretylium tosylate (BT)

178 While the alpha2-antagonists, yohimbine, rauwolscine and idazoxan blocked NE-induced i

179 classic alpha2 receptor antagonists, such as yohimbine, rauwolscine, and atipamezole.

180 i) UK 14,304 constricted MV but not MA while yohimbine reduced constrictions in MV but not MA.

181 ombined administration of hydrocortisone and yohimbine reduced the sensitivity of the orbitofrontal a

182 lactate infusions or the noradrenergic agent yohimbine reliably induce panic attacks in humans with p

183 taneous administration of hydrocortisone and yohimbine renders instrumental behavior insensitive to t

184 013) and 15% (P=0.004) with phentolamine and yohimbine, respectively.

185 Yohimbine resulted in a significant increase in anxiety

186 h the alpha-2 adrenergic receptor antagonist yohimbine results in a marked down-regulation of tyrosin

187 BSTv infusion of idazoxan did not reproduce yohimbine's anxiogenic effects and anxiety was not reduc

188 Yohimbine selectively elevates self-rated anxiety in chi

189 Yohimbine-stimulated Deltamax growth hormone (GH) for ch

190 Intravenous or i.c.v. pretreatment with yohimbine, the alpha2-adrenoceptor and 5-HT1A receptor a

191 Pretreatment with yohimbine, the alpha2-adrenoceptor antagonist (8 microg;

192 yrosinase activity is markedly suppressed by yohimbine, the compound has no effect on cell proliferat

193 lpha 2-adrenoceptor antagonists idazoxan and yohimbine, the noradrenaline-depleting drug reserpine an

194 In the presence of yohimbine, the rate of biosynthesis of ferritin in a cel

195 ected by the alpha 2-adrenoceptor antagonist yohimbine, the serotonergic receptor antagonist methyser

196 C) was also assessed owing to the ability of yohimbine to activate the hypothalamic-pituitary-adrenal

197 lly specific attenuation of fear produced by yohimbine transferred to another extinguished conditiona

198 Except for saline placebo and yohimbine-treated animals, comparable increases in coron

199 Yohimbine treatment facilitated extinction in 129S1, but

200 ended training, as well as d-cycloserine and yohimbine treatment.

201 , and alpha2-adrenergic receptor antagonist (yohimbine; used as a pharmacological stressor).

202 The natural product yohimbine was found (based on gel mobility shifts) to bl

203 The SBP response to yohimbine was greater in patients with MSA than in those

204 Yohimbine was uniformly well tolerated, and it behaviora

205 In the present study, yohimbine was used as a probe of noradrenergic activity,

206 Although the actions of yohimbine were not mimicked by the norepinephrine transp

207 Beneficial effects for yohimbine were readily evident for self-report measures

208 The results suggest that yohimbine, when administered in the presence of a neutra

209 wing administration of the beta 2-antagonist yohimbine, which stimulates brain norepinephrine release

210 We recorded the distribution of (11)C-yohimbine with 90-min dynamic PET and sampled arterial b

211 r antagonists has been identified based upon yohimbine, with SAR studies resulting in a 1000-fold inc

212 initial administration of clonidine (CLO) or yohimbine (YHO).

213 tion of the alpha(2)-adrenoceptor antagonist yohimbine (YO) activates the HPA stress axis and promote

214 The alpha2 adrenoceptor antagonist yohimbine (YO) increases transmitter release from adrene

215 The alpha2-adrenoceptor antagonist yohimbine (YOH) was injected i.p. or perfused locally in

216 Yohimbine (Yoh, alpha(2)-adrenoceptor antagonist) or BIB